Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic bone marrow transplantation for acute leukemia.

S J Forman1, K G Blume

  • 1Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, California.

Hematology/Oncology Clinics of North America
|June 1, 1990
PubMed
Summary

Allogeneic marrow transplantation offers a cure for acute leukemia, with long-term survival rates up to 60% for acute myelogenous leukemia and high-risk acute lymphoblastic leukemia. Ongoing research focuses on improving preparatory regimens and managing complications to enhance patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Leukemia·2016
Same author

Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

Bone marrow transplantation·2014
Same author

Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2014
Same author

Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation.

Bone marrow transplantation·2014
Same author

Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Gene therapy·2013

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Allogeneic marrow transplantation is a curative option for acute leukemia.
  • Patient remission status significantly impacts treatment success.
  • Therapy-related leukemias and older patients (up to 50 years) can also benefit.

Purpose of the Study:

  • To review the efficacy of allogeneic marrow transplantation in treating acute leukemia.
  • To highlight factors influencing successful outcomes, including remission status and patient age.
  • To discuss ongoing advancements aimed at improving transplantation results.

Main Methods:

  • Review of current literature and clinical studies on allogeneic marrow transplantation for acute leukemia.
  • Analysis of survival data based on leukemia type and remission status.

Related Experiment Videos

  • Evaluation of strategies to mitigate transplant-related complications.

    • Main Results:

    • Up to 60% long-term disease-free survival is achievable for acute myelogenous leukemia and high-risk acute lymphoblastic leukemia.
    • Allogeneic marrow transplantation is effective in patients up to 50 years old and those with therapy-related leukemias.
    • Relapse remains a challenge, but advancements are being made.

    Conclusions:

    • Allogeneic marrow transplantation is a vital curative therapy for acute leukemia.
    • Improved preparatory regimens, graft-versus-host disease management, and cytomegalovirus pneumonia prevention are key to enhancing outcomes.
    • Continued research promises further improvements in allogeneic marrow transplantation for acute leukemia patients.